Background: Widespread restructuring of health delivery systems is underway in the United States to reduce costs and improve the quality of health care.
I n the United States, approximately one fifth of spending is dedicated to health care. Recognition of lack of transparency, fragmentation, and the poor return for high spending has led to broad agreement about the need for fundamental change in the United States health care system to both lower costs and improve quality. The concept of improving "value" has emerged to frame needed reforms. 1, 2 Value can be understood as the balance between care quality (in terms of patient satisfaction and health outcomes) and expenditures, although specific definitions vary among stakeholders. 2, 3 By 2013, several national policy organizations had proposed reforms to promote structural change and improve value in health care delivery. 4 Although some have questioned the likely impact of these interventions, 5 medical homes, value-based purchasing, and pay-for-performance programs were endorsed consistently across organizations, leading government, insurers, and health plans to incentivize these strategies to improve value. Such efforts have led to demonstration and pilot projects with a rapidly expanding literature describing interventions and their outcomes. Early reports suggest that pilot project interventions have led to improvements in quality while reducing spending. 6 To enhance our understanding of the potential impact of structural reforms on the health care system, we performed a systematic review of the effect of system-level interventions on the value of health care in the United States and present descriptions of relevant studies.
METHODS

Overview
We performed a systematic review of system-level US interventions which reported the components of value. We used the PRISMA statement on systematic reviews of studies reporting health care interventions 7 to guide the methods. We defined system-level interventions as those that broadly altered either payment methods (eg, pay-for-performance) or health care delivery structure [eg, the patient-centered medical home (PCMH) model].
Framework for "Value"
Definitions of value vary based on stakeholder. 2 Although different health systems establish variable thresholds for determining the cost-effectiveness of interventions, 8 all would agree that improved outcomes at fixed or lower cost represent improved value. We included papers assessing both quality of care (including patient satisfaction) and either the cost of care or health services utilization, which is often used as a proxy for cost. 9 We conceptualized value as the balance between quality and cost or utilization, defining value improvement as better quality with lower or constant cost/utilization.
Study Identification and Data Extraction
We conducted a MEDLINE search (PubMed interface) for studies published from January 1, 2003 through July 23, 2014, limited to human subjects, English language, and titles with abstracts. We used an iterative process to identify search terms ( Fig. 1 ) and identified additional articles through author and reference tracking. To update our results, we searched tables of contents of relevant journals published between August 1, 2014 and August 11, 2015, for articles potentially meeting inclusion criteria. See Supplementary Digital Content 1, (http://links.lww.com/MLR/B35) for details of study identification and data extraction.
We included controlled studies evaluating the impact of system-level interventions on value in general clinical environments (eg, physician's offices, hospitals). All papers were reviewed by 1 investigator (M.J.D., K.D., D.K., S.K.). A random sample of 296 full-text articles were reviewed by one of 2 pairs of investigators for determination of interrater reliability (Cohen). Figure 2 demonstrates the flow of articles in the review.
Data extraction was performed by 1 reviewer (R.A., K.D., M.J.D., D.K., or S.K.) and checked by a second reviewer (R.A. or D.K.) for accuracy. Differences were resolved by discussion and consensus.
Assessment of Study Quality
We collected information related to study quality using applicable components of the Cochrane risk of bias tools for cohort and randomized studies. 10, 11 For randomized trials, we recorded the completeness of follow-up and whether the randomization method was described 10 ; for observational studies we recorded whether confounders were assessed and whether adjustments were made for confounders. 11
Determination of Value
We defined increased value as either (1) increased quality with no change or reduction in cost/utilization; or (2) no change in quality with lower cost/utilization. We defined decreased value as (1) reduced quality with no change or increase in cost/utilization; or (2) no change in quality with an increase in cost/utilization. Changes were defined as marginal when only one of multiple reported measures was significantly changed. We defined value as unchanged if both quality and cost/utilization were unchanged. We defined value as mixed when reported measures of quality or cost/ utilization changed in opposite directions (eg, 2 quality measures were reported, with 1 improving and 1 worsening) or when both quality and cost/utilization increased or decreased. Although we recognize that some definitions of value (eg, those based on cost-effectiveness) would allow for determinations of value in situations we deemed "mixed" such as when both quality and cost increase, cost-effectiveness and relevant thresholds are rarely reported. We defined value as unclear when the data presented were insufficient to draw conclusions (eg, statistical significance not reported).
Data Analysis
Interrater reliability for the decision to include the article in the review was moderate to high (Cohen k, 0.83 and 0.58 for the 2 investigator pairs). Given differences in interventions, study populations, study designs, and outcome measures, we did not attempt to pool study results; instead we present descriptive information.
RESULTS
Our initial search yielded 10,960 articles; 10,664 were excluded in title and abstract review. Including the updated search, 29 articles describing 29 studies of 28 interventions were included in the review (Fig. 2 ). One article described 2 interventions, and 3 articles described 2 studies of 1 intervention (the 3 articles all presented unique data and are listed separately, resulting in 30 reports described in Tables 1 and 2 ). Table 1 describes study characteristics of the 30 separate included reports. Fourteen interventions were primarily PCMH implementations, 9,12-23 10 were pay-for-performance programs, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] and 6 were mixed with features of both intervention types. [34] [35] [36] [37] [38] [39] Study quality varied. There was 1 randomized trial 35 ; the method of randomization, drop-outs, and follow-up were well described. Among the remaining observational studies, 22 adjusted fully for confounding factors, 5 performed partial adjustment, and 2 did not adjust for confounders.
Characteristics of Included Studies
Impact of Interventions on Quality
Reported quality indicators varied widely (Table 2) and most studies reported multiple quality outcomes (predominantly process measures). The most commonly reported outcome was the rate of hemoglobin A1C testing in diabetic patients (14 studies), followed by lipid testing rates (14 studies), cancer screening rates (11 studies), readmission rates (7 studies), composite quality measures (5 studies), patient satisfaction (5 studies), and diabetes control (5 studies). Measures of overuse were reported in 2 studies; a PCMH intervention reported unnecessary imaging for low back pain 19 and a pay-for-performance intervention reported unnecessary pharyngitis testing 26 ; rates of overuse declined in both. Mortality was reported in 1 study of a pay-for-performance intervention 33 and did not decline significantly in the intervention group.
Overall, 17 studies found net improvement in quality (although often some measures were unchanged or reduced), 5 found marginal improvement, 3 found no change, 1 found marginal decline in quality, 1 found no change, and 3 had unclear results ( Table 2 ).
Impact of Interventions on Cost and Utilization
Most reports (n = 19) described both cost and utilization outcomes; 5 reported only cost and 6 reported only utilization ( Table 2 ). Specific cost and utilization outcomes varied widely. Utilization outcomes generally focused on rates of outpatient visits, emergency department visits, and hospitalization. Several studies reported total cost per-beneficiary over a defined time period.
Impact of Interventions on Value
There were 30 reports from which we summarized the impact on value ( Table 2) . Value was improved in 17, marginally improved in 6, marginally lower in 1, unchanged in 1, and unclear or mixed in 5. Given the variability in specific outcome measures, direct comparisons of the impact of different interventions on value cannot be made.
DISCUSSION
In this systematic review, we describe system-level interventions for which value-relevant outcomes have been reported. Interventions included PCMH implementations, pay-for-performance initiatives, and programs with features of both. We found wide variability in study quality and reported outcome measures. The limited available evidence suggests that PCMH and pay-for-performance initiatives improve value, but the magnitude and importance of this improvement is not clear.
We defined value loosely for the purposes of this review, crediting improved value when improvements in quality, cost, or utilization were very small, clinically trivial, or limited to patients with specific diagnoses. This approach likely overestimated value improvements. We opted to loosely define value so our findings will reflect the majority of published studies of system interventions so far. However, given the importance of optimizing value, it will be critical for future studies to measure outcomes that facilitate meaningful value calculations and to include broad patient populations. Further, as experts attempt to estimate the impact of care delivery innovations across the US health care system, thresholds for important changes in value will need to be established. Quality is an important driver of value but some quality outcomes are more meaningful than others. We credited "marginal" quality improvement when at least one of many measures improved, which may have overestimated value improvements. If we applied a more stringent definition of improved value, requiring improvement in at least 2 measures of quality or cost/utilization, the majority of studies (17/30) still found that value improved. However, most reported quality outcomes involved process measures (eg, the proportion of diabetic patients in whom HbA1C was checked) and not outcome measures (eg, improvements in HbA1C values). There were few changes in measures of clinical outcomes; indeed none of the most recent studies (published in 2014 or 2015) found improvements in outcome measures; 3 evaluated no outcome measures and 4 included them but found that they did not improve. This failure to impact outcome measures is important. Although process measures can predict meaningful patient outcomes, 40, 41 their association with clinical improvements may be limited 42 and they may poorly reflect population health. 43 Further, observed quality improvements were often of small magnitude ( Table 2 ). The clinical importance of these changes is unclear; assessment of true clinical outcomes rather than process measures would facilitate a richer understanding of the impact of system-level interventions.
Cost outcomes were similarly heterogeneous. Among the 8 highest quality studies, only 3 found lower cost, each using a different approach to measure costs. And it is notable that these assessments did not include costs associated with practice transformation or incentive payments. Standard cost measures are needed to facilitate direct comparison and estimation of the likely impact of larger-scale interventions. Several studies measured cost as total dollars spent per patient per month; this seems the most appropriate standard for use in future studies.
It is notable that only 2 evaluations in our review addressed overuse, which contributes to both poor quality and higher costs. 44 Both studies found a reduction in overuse. However, the exclusion of overuse outcomes from the majority of studies is problematic as it is important that systemlevel interventions successfully minimize overuse.
Our study has important limitations. As utilization is a proxy for cost, we included studies which measured utilization and not cost. However, utilization may be a poor measure of cost. 45 In addition, we did not include cost-effectiveness when conceptualizing value; indeed cost-effectiveness was not reported in any identified studies and was beyond the scope of these studies. Limiting our review to studies evaluating cost-effectiveness would have limited its scope. However, attention to cost-effectiveness will be critical to more nuanced future assessments of value. Further, there are no specific MeSH terms for health care value, so our search may have failed to identify studies. However, extensive reference and author tracking make it unlikely that we missed large important studies. Finally, we focused primarily on value, for which there is no standard calculation method. Our intentionally liberal approach is meant to be descriptive and may have overestimated the impact of interventions.
In conclusion, there is a small emerging body of literature on PCMH and pay-for-performance interventions that suggest that these interventions may to some extent improve value. However, despite the broad nation-wide movement toward these system-level reforms, we found only 30 assessments of their impact on value. Further, studies to date are methodologically limited and the diversity of specific measures preclude direct comparisons among interventions. Standardization of the definition of value and the measures used to assess value and replication of our findings under more standardized conditions are critical for optimizing the evidence base to inform system-wide change.
